PERTH, Australia – Radiopharm Theranostics Ltd. raised AU$50 million (US$36.4 million) in an oversubscribed IPO to advance its platform of radiopharmaceutical products for both diagnostic and therapeutic uses.
The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to provide Clover Biopharmaceuticals Ltd. with an additional $36.9 million to support development of SCB-2019, a recombinant trimeric Spike-protein subunit COVID-19 vaccine.
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. was listed on the Shanghai Stock Exchange Star Market in China on Nov. 15, with the share prices jumping 71.16% on the first day. Aohua Endoscopy offered 33.34 million shares at ¥22.5 (US$3.53) per share. It raised ¥750 million in this IPO, higher than projected ¥640 million it projected to raise.
As the COVID-19 pandemic emerged in early 2020 and med-tech companies stepped up with numerous diagnostic and telehealth solutions, the availability of funding sources began to soar. The med-tech industry has raised a total of $46.9 billion so far in 2021 through 636 financings.
Glyconics Ltd. landed £1.5 million (US$2 million) in an Enterprise Investment Scheme funding round to finance a clinical trial of its diabetes screening tool, Glyconics-SX. The Cambridge, U.K.-based diagnostics company is developing a point-of-care, hand-held device using miniaturized infrared (IR) spectrometry. The technology scans fingernails, assessing glycation to identify diabetes within minutes.
Assure Tech (Hangzhou) Co. Ltd. made its debut on the Shanghai Stock Exchange Star Market and raised ¥1.2 billion (US$188 million) in the IPO. Its shares increased 19.28% in the middle of the first trading day but closed 6.73% lower the second day.